Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19045171 | 1.00 | KDM4E (0.48) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL7436133 | 0.83 | — | — | |
| SCHEMBL11075525 | 0.80 | KDM4E (0.67) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL21717783 | 0.77 | — | — | |
| SCHEMBL28194021 | 0.77 | — | — | |
| SCHEMBL28306550 | 0.74 | SMN1; SMN2 (0.39) | KDM4ELMNACYP2C19SMN1; SMN2 | |
| SCHEMBL24615964 | 0.73 | SMN1; SMN2 (0.45) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL16885243 | 0.73 | SMN1; SMN2 (0.45) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL21557423 | 0.72 | LMNA (0.50) | KDM4ELMNACYP2C19SMN1; SMN2TSHR | |
| SCHEMBL1665837 | 0.71 | SMN1; SMN2 (0.38) | KDM4ELMNACYP2C19SMN1; SMN2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242285-B2 | N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| EP-2008999-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163722-A1 | N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF | TERT, CBR1, TELO2 | KDM4E 424/4885LMNA 1442/4885CYP2C19 933/4885 |
| US-20100280259-A1 | N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof | TERT, CBR1, TELO2 | KDM4E 424/4885LMNA 1442/4885CYP2C19 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.